These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23357766)

  • 41. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
    Ruslami R; Nijland HM; Alisjahbana B; Parwati I; van Crevel R; Aarnoutse RE
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2546-51. PubMed ID: 17452486
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
    Pasipanodya JG; Nuermberger E; Romero K; Hanna D; Gumbo T
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S10-7. PubMed ID: 26224767
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic drug monitoring in the treatment of tuberculosis.
    Peloquin CA
    Drugs; 2002; 62(15):2169-83. PubMed ID: 12381217
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model.
    Balasubramanian V; Solapure S; Gaonkar S; Mahesh Kumar KN; Shandil RK; Deshpande A; Kumar N; Vishwas KG; Panduga V; Reddy J; Ganguly S; Louie A; Drusano GL
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3054-7. PubMed ID: 22470118
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rifampin pharmacokinetics in tuberculosis-diabetes mellitus patients: a pilot study from Baja California, Mexico.
    Perea-Jacobo R; Muñiz-Salazar R; Laniado-Laborín R; Cabello-Pasini A; Zenteno-Cuevas R; Ochoa-Terán A
    Int J Tuberc Lung Dis; 2019 Sep; 23(9):1012-1016. PubMed ID: 31615609
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical Pharmacokinetics of Rifampin in Patients with Tuberculosis and Type 2 Diabetes Mellitus: Association with Biochemical and Immunological Parameters.
    Medellín-Garibay SE; Cortez-Espinosa N; Milán-Segovia RC; Magaña-Aquino M; Vargas-Morales JM; González-Amaro R; Portales-Pérez DP; Romano-Moreno S
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7707-14. PubMed ID: 26438503
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs.
    Dutta NK; Alsultan A; Peloquin CA; Karakousis PC
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1535-7. PubMed ID: 23295923
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Measurement of the concentration of three antituberculosis drugs in the focus of spinal tuberculosis.
    Ge Z; Wang Z; Wei M
    Eur Spine J; 2008 Nov; 17(11):1482-7. PubMed ID: 18795341
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens.
    Srivastava S; Gumbo T
    Curr Pharm Des; 2011; 17(27):2881-8. PubMed ID: 21834761
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions.
    Ordonez AA; Wang H; Magombedze G; Ruiz-Bedoya CA; Srivastava S; Chen A; Tucker EW; Urbanowski ME; Pieterse L; Fabian Cardozo E; Lodge MA; Shah MR; Holt DP; Mathews WB; Dannals RF; Gobburu JVS; Peloquin CA; Rowe SP; Gumbo T; Ivaturi VD; Jain SK
    Nat Med; 2020 Apr; 26(4):529-534. PubMed ID: 32066976
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.
    Verhagen LM; López D; Hermans PW; Warris A; de Groot R; García JF; de Waard JH; Aarnoutse RE
    Trop Med Int Health; 2012 Dec; 17(12):1449-56. PubMed ID: 23094704
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir.
    Rabie H; Tikiso T; Lee J; Fairlie L; Strehlau R; Bobat R; Liberty A; McIlleron H; Andrieux-Meyer I; Cotton M; Lallemant M; Denti P
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071055
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of antituberculosis drugs in patients.
    Israili ZH; Rogers CM; el-Attar H
    J Clin Pharmacol; 1987 Jan; 27(1):78-83. PubMed ID: 3680559
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients.
    Lyons MA
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661865
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.
    De Groote MA; Gilliland JC; Wells CL; Brooks EJ; Woolhiser LK; Gruppo V; Peloquin CA; Orme IM; Lenaerts AJ
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1237-47. PubMed ID: 21135176
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in tuberculosis patients.
    Chang MJ; Chae JW; Yun HY; Lee JI; Choi HD; Kim J; Park JS; Cho YJ; Yoon HI; Lee CT; Shin WG; Lee JH
    Tuberculosis (Edinb); 2015 Jan; 95(1):54-9. PubMed ID: 25482224
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea.
    Choudhri SH; Hawken M; Gathua S; Minyiri GO; Watkins W; Sahai J; Sitar DS; Aoki FY; Long R
    Clin Infect Dis; 1997 Jul; 25(1):104-11. PubMed ID: 9243044
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications.
    Guiastrennec B; Ramachandran G; Karlsson MO; Kumar AKH; Bhavani PK; Gangadevi NP; Swaminathan S; Gupta A; Dooley KE; Savic RM
    Clin Pharmacol Ther; 2018 Oct; 104(4):733-741. PubMed ID: 29247506
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice.
    Vilchèze C; Kim J; Jacobs WR
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29298757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.